Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Roth AD, et al. Among authors: rufibach k. J Clin Oncol. 2007 Aug 1;25(22):3217-23. doi: 10.1200/JCO.2006.08.0135. J Clin Oncol. 2007. PMID: 17664469 Clinical Trial.
Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.
Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, Pestalozzi B, Schmid S, Thöni A, Ozsahin M, Bernier J, Töpfer M, Kann R, Meier UR, Thum P, Bieri S, Notter M, Lombriser N, Glanzmann C. Huguenin P, et al. Among authors: rufibach k. J Clin Oncol. 2004 Dec 1;22(23):4665-73. doi: 10.1200/JCO.2004.12.193. Epub 2004 Nov 8. J Clin Oncol. 2004. PMID: 15534360 Clinical Trial.
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK).
Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Léger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF. Ghielmini M, et al. Among authors: rufibach k. Ann Oncol. 2005 Oct;16(10):1675-82. doi: 10.1093/annonc/mdi320. Epub 2005 Jul 19. Ann Oncol. 2005. PMID: 16030029 Free article. Clinical Trial.
Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort.
Ciurea A, Scherer A, Exer P, Bernhard J, Dudler J, Beyeler B, Kissling R, Stekhoven D, Rufibach K, Tamborrini G, Weiss B, Müller R, Nissen MJ, Michel BA, van der Heijde D, Dougados M, Boonen A, Weber U; Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis. Ciurea A, et al. Among authors: rufibach k. Arthritis Rheum. 2013 Dec;65(12):3096-106. doi: 10.1002/art.38140. Arthritis Rheum. 2013. PMID: 23983141 Free article.
Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO).
Allal AS, Ares C, Dulguerov P, Tschanz E, Verdan C, Mhawech P, Riesterer O, Honer M, Vuong V, Jochum W, Zingg D, Bodis S, Ametamey S, Pruschy M, Inteeworn N, Ohlerth S, Höpfl G, Roos M, Wergin M, Rohrer Bley C, Gassmann M, Kaser-Hotz B, Berthou S, Aebersold DM, Ganapathipillai S, Streit B, Stalder D, Gruber G, Greiner RH, Zimmer Y, Lutters G, Krek W, Tenzer A, Hofstetter B, Bonny C, Azria A, Larbouret C, Cunat S, Ozsahin M, Zouhair A, Gourgou S, Martineau P, Evans DB, Romieu G, Pujol P, Pèlegrin A, Heuberger J, Kestenholz P, Taverna Ch, Lardinois D, Jörger M, Schneiter D, Jerman M, Weder W, Stahel R, Bodis S, Vees H, Mach N, Hügli A, Balmer Majno S, Beer KT, Friedrich EE, Ciernik IF, Stanek N, Taverna C, Greiner R, Mahler F, Landmann Ch, Studer G, Bernier J, Gallino A, Juelke PD, Hafner HP, Jamshidi P, Erne P, Resink TJ, Thum P, Notter M, Bargetzi M, Suleiman M, Luthi JC, Bieri S, Curschmann J, Pajic B, Kranzbühler H, Lippold B, Ueltschi G, Bonetti M, Nasi ML, Price KN, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Gol-Ouh R, Collins J, Crivellari D, Carbone A, Thürlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Goldhirsch A, Jeanneret Sozzi W, Kramar A, Mirim… See abstract for full author list ➔ Allal AS, et al. Among authors: rufibach k. Strahlenther Onkol. 2004 Jun;180 Suppl 1:89-108. doi: 10.1007/BF03356735. Strahlenther Onkol. 2004. PMID: 27137923 No abstract available.
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Marcus R, et al. Among authors: rufibach k. N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598. N Engl J Med. 2017. PMID: 28976863 Free article. Clinical Trial.
96 results